Three heart failure patients with pulmonary hypertension (WHO Group II) became eligible for heart transplants after receiving the Aeson Total Artificial Heart, which effectively took place after 243, 155 and 109 days respectively. This innovative device, implanted with the help of the advanced Carmat system, replaces the heart’s ventricles and maintains continuous blood circulation, stabilizing patients with severe heart failure.
Up to 25% of patients with advanced heart failure suffer from pulmonary hypertension, which represents several thousand patients in a difficult-to-treat situation, as they are mostly subject to a contra-indication to heart transplant. The successful use of the Aeson Total Artificial heart as a bridge to transplantation offers new hope for these patients, showcasing the potential of cutting-edge medical technology in transforming patient care.
Read the full article at this link on The Journal of Heart and Lung Transplantation.
Disclaimer
This is a single center study on very few patients so more research is needed. It could potentially be interesting if applicable to other forms of pulmonary hypertension (eg. pulmonary arterial hypertension, WHO Group I) as a bridge to lung transplantation but this needs to be verified.
Citation
Precise Monitoring of Transpulmonic Resistance in Bridge to Transplant Patients Supported by The Aeson Total Artificial HeartPya, Yuriy et al. The Journal of Heart and Lung Transplantation, Volume 0, Issue 0, DOI: 10.1016/j.healun.2025.02.00